Everyone understands that antibiotics are a vital weapon in fighting bacterial infections. What you may not know is that it works by inhibiting the bacteria’s cell wall synthesis, thus weakening and killing the toxic bacteria in the process. There was no compound that worked in this way with fungal cells – UNTIL NOW!

CANDIDA RELEASE is a Chitin synthesis inhibitor and is truly revolutionary as it works in EXACTLY the same way as an antibiotic with the difference being it interferes with the fungal cell wall production (just the same as an antibiotic does with bacteria) and leaves the fungus weakened and vulnerable.

The future of anti fungals is really starting here with this revolutionary new approach! We have worked hard to bring you this information and we welcome any questions and comments or if you would like to tell us your experience with candida. If you want to contact us please see the Contact US page.


The present invention relates to a new use of benzoylphenylureas derivatives. More particularly, the present invention relates to benzoylphenylureas derivatives for use in combating fungal infections.

Fungi are causative agents of various superficial skin lesions. The fungi live on the surface of the skin and use keratin as major solutions of nutrients. Fungi are found on various skin regions including in the legs, in the genital area, below the nails, etc. In addition, occasionally, particularly in individuals with an immune deprivation, fungi can develop on various other tissues such as on the oral mucosa. Furthermore, there are occasional fungi infections which may be systemic.

The fungi cells are typically surrounded by cell walls that contain complex polysaccharides, primarily chitin, chitosan, glucans and mannans. U.S. Pat. No. 4,798,837, discloses N-benzoyl-N’-2,5-dichloro-4-hexafluoropropyloxy-phenylureas which were found to be effective. One of these compounds, known by the generic name is Lufenuron.

In accordance with the invention it was found that Lufenuron administration is effective in combating and controlling fungal infection, especially such caused by dermatophytes. The term “effective amount” should be understood as meaning an amount effective in achieving a therapeutic effect which may be manifested either in a permanent or temporary improvement in the subject’s condition, or in reduction of a fungal infection load. The effective amount may depend, inter alia, on the therapeutic regiment, the type of infection being treated, namely whether it is systemic, topical, etc., on the type of subject treated, i.e. whether it is human or a non human animal, as well as the type of animal, on the age of the subject, etc.

The pharmaceutical composition of the invention may, for example be provided in the form of a powder, lyophilizate, etc., for mixing with a physiological solution, e.g. saline for the purpose of parenteral administration. By a further example, the pharmaceutical solution of the invention may be formulated as an oral dosage form, e.g. in the form of a pill or a capsule. In addition, for some applications, the pharmaceutical composition of the invention may also be formulated in the form of a liquid solution intended for oral administration. Furthermore, the composition of the invention may also be formulated for topical administration.

The invention allows a therapeutic treatment of a variety of fungal infections. These include systemic infections as well as topical fungal infections. In particular, and by a preferred embodiment, the present invention allows treatment of skin fungal infections in both humans and animals, nail or genital fungal infections in humans, eye fungal infections or ear fungal infections in both humans and animals, and others. Particular examples of fungal infections which may be treated in accordance with the invention are caused by dermatophytes such as those of the genus Microsporum (e.g. Microsporum Canis) which cause various skin fungal infections of the skin, nails or hair; those of the genus Aspergillas, and yeasts, e.g. Malassezia or Candida.